Contract Manufacturing of Clinical-Trial Products for Janssen Pharma
First written in FY2021-Q3. 3 of 4 entries say "Advanced", first in FY2023. Latest entry: 2026-05-27.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- 2026-05-27AdvancedPresentation materials on financial results
「Completion of contract manufacturing of the investigational product」
Contract manufacturing of an investigational product for Janssen Pharma has been completed, and preparations continue for a system capable of contract manufacturing of commercial products. - FY2025AdvancedAnnual report
「In the CDMO Business, while contract manufacturing from the former Janssen Pharmaceutical Co., Ltd. continued」
Contract manufacturing of clinical trial products for Janssen Pharmaceutical continued, with annual sales reaching ¥102.404 million. - FY2023AdvancedAnnual report
「Janssen Pharmaceutical Co., Ltd. 69,642 10.5」
For the contract manufacture of clinical trial products for Janssen Pharmaceutical, annual sales of ¥69.642 million and 10.5% of total sales were disclosed. - FY2021-Q3First statedAnnual report
「Technology transfer for manufacturing investigational products for Janssen Pharma, which had been under way for some time, was completed. In May 2021, we entered into a contract manufacturing agreement with Janssen Pharma for investigational products. Under the agreement, we undertook part of the manufacturing process for investigational products used in the Japanese portion of the international joint clinical trial, the Phase III CARTITUDE-4 trial, conducted by Janssen Pharma, and began manufacturing in June 2021.」
The Company completed technology transfer with Janssen Pharma, signed a contract manufacturing agreement and began manufacturing investigational products for the Japanese portion of CARTITUDE-4.